公开(公告)号：AU2015333590B2

公开(公告)日：2021-03-11

申请号：AU2015333590

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: C07K16/22 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.

公开(公告)号：AU2017225906A1

公开(公告)日：2018-10-11

申请号：AU2017225906

申请日：2017-03-01

Applicant: CELLMID LTD

Inventor： JONES DARREN ,  HALASZ MARIA ,  LIEDERT ASTRID ,  HAFFNER-LUNTZER MELANIE ,  IGNATIUS ANITA

IPC: A61K39/395 ,  A61P19/08

Abstract: The present disclosure relates to methods and reagents for treating bone disorders and/or increasing bone healing. In particular, present disclosure relates to the use of isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (hereinafter, referred to as "MK") in the treatment of bone disorders and/or to increase bone healing.

公开(公告)号：AU2015333590A1

公开(公告)日：2017-04-20

申请号：AU2015333590

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: C07K16/22 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.

公开(公告)号：AU2014361754A1

公开(公告)日：2016-06-23

申请号：AU2014361754

申请日：2014-12-12

Applicant: CELLMID LTD

Inventor： YAMAMOTO MASAKUNI ,  NAMEKATA MASAO ,  YAMAUCHI KOICHI ,  MATSUMOTO TAKEO ,  JONES DARREN ROSS ,  HALASZ MARIA

IPC: A61K31/122 ,  A61K8/34 ,  A61K8/35 ,  A61K8/37 ,  A61K31/045 ,  A61K31/22 ,  A61P17/00 ,  A61P17/14 ,  A61Q7/00

Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signalling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signalling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.

公开(公告)号：AU2014361754B2

公开(公告)日：2020-04-30

申请号：AU2014361754

申请日：2014-12-12

Applicant: CELLMID LTD

Inventor： YAMAMOTO MASAKUNI ,  NAMEKATA MASATO ,  YAMAUCHI KOICHI ,  MATSUMOTO TAKEO ,  JONES DARREN ROSS ,  HALASZ MARIA

IPC: A61K31/122 ,  A61K8/34 ,  A61K8/35 ,  A61K8/37 ,  A61K31/045 ,  A61K31/22 ,  A61P17/00 ,  A61P17/14 ,  A61Q7/00

Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signalling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signalling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.

公开(公告)号：EP3079679A4

公开(公告)日：2017-06-07

申请号：EP14869892

申请日：2014-12-12

Applicant: CELLMID LTD

Inventor： YAMAMOTO MASAKUNI ,  NAMEKATA MASATO ,  YAMAUCHI KOICHI ,  MATSUMOTO TAKEO ,  JONES DARREN ROSS ,  HALASZ MARIA

IPC: A61K31/122 ,  A61K8/34 ,  A61K8/35 ,  A61K8/37 ,  A61K31/045 ,  A61K31/22 ,  A61P17/00 ,  A61P17/14 ,  A61Q7/00

CPC classification number: A61K31/22 ,  A61K8/33 ,  A61K8/34 ,  A61K8/35 ,  A61K8/37 ,  A61K9/0014 ,  A61K31/045 ,  A61K31/11 ,  A61K31/122 ,  A61K2800/74 ,  A61Q7/00 ,  A61Q13/00 ,  A61K2300/00

Abstract: The present application generally relates to topical formulations comprising monoterpenoid compounds which are effective inhibitors of FGF-5-dependent signaling in hair follicles or parts thereof, the manufacture of such topical formulations, and their use to reduce, delay or prevent loss of terminal hair caused by FGF-5 signaling in the hair follicle, such as in subjects suffering from, or having a propensity to develop, alopecia.

Abstract translation: 本申请一般涉及包含单萜化合物的局部制剂，所述单萜化合物是毛囊或其部分中FGF-5依赖性信号传导的有效抑制剂，这种局部制剂的制造，以及它们用于减少，延迟或防止引起的末发损失 通过毛囊中的FGF-5信号转导，例如患有或有倾向发展为脱发的受试者

公开(公告)号：EP3206712A4

公开(公告)日：2018-03-21

申请号：EP15849875

申请日：2015-10-14

Applicant: CELLMID LTD

Inventor： HALASZ MARIA ,  JONES DARREN ,  MERTENS NICO ,  CUNNAH PHILLIP

IPC: A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  C07K16/22

CPC classification number: C07K16/22 ,  A61K31/555 ,  A61K39/3955 ,  A61K39/39558 ,  A61K47/48546 ,  A61K47/48569 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/626 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/57407 ,  G01N33/57434 ,  G01N33/57488 ,  G01N33/6893 ,  G01N33/74 ,  G01N2333/475

Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.

公开(公告)号：EP2686016A4

公开(公告)日：2014-09-03

申请号：EP12757658

申请日：2012-03-13

Applicant: CELLMID LTD

Inventor： SAKUMA SADATOSI ,  HALASZ MARIA ,  JONES DARREN

IPC: A61K39/395 ,  A61P25/28 ,  A61P37/00 ,  C07K16/22

CPC classification number: C07K16/22 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to isolated or recombinant proteins, such as antibodies, which inhibit or reduce the function of midkine (hereinafter, referred to as “MK”) for use in the treatment or prevention of midkine-related disorders.